Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial

Abstract

This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) vs insulin glargine U100 (IGlar) across categories of baseline glycated haemoglobin (HbA1c; ≤7.5%, >7.5% to ≤8.5% and >8.5%), body mass index (BMI; <30, ≥30 to <35 and ≥35 kg/m2 ) and fasting plasma glucose (FPG; <7.2 and ≥7.2 mmol/L) in patients with type 2 diabetes (T2D… (More)
DOI: 10.1111/dom.13043

Topics

2 Figures and Tables

Cite this paper

@inproceedings{Lingvay2018InsulinD, title={Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial}, author={Ildiko Lingvay and Stewart Harris and Elmar Jaeckel and Keval Chandarana and Mattis Flyvholm Ranthe and Esteban J{\'o}dar}, booktitle={Diabetes, obesity & metabolism}, year={2018} }